Ascendis Pharma A/S vs S&P Global Inc — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.67B), while S&P Global Inc trades at $409.33 (market cap $120.48B). The key difference: S&P Global Inc is far larger — about 7.2× Ascendis Pharma A/S's market cap, and S&P Global Inc pays a 0.95% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SPGI | |
|---|---|---|
Market Cap | $16.67B | $120.48B |
Sector | Health | Financials |
52-Week High | $277.18 | $534.79 |
52-Week Low | $189.74 | $370.42 |
Enterprise Value | $17.04B | $131.97B |
Dividend Yield | — | 0.95% |
Trailing returns across standard periods
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →